HomeStartups 89bio lifecycle

Claimed by owner Last Update Oct 29, 2025 Suggest Edits Claim Profile

Claimed by owner

89bio

Treatment for Liver and Metabolic Disorders

ACQUIRED by Roche on Sep, 2025

89bio

89bio Overview

Cumulative Funding Raised Over Time ($)

Employees Over Time

Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics

#Acquisition #Partners

8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors

#Investment

Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $5.2 Billion Buyout

#Acquisition

Assessing 89bio (ETNB) Valuation Following a 60% Share Price Rally

Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash

#Acquisition

89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal

#Acquired-by

89Bio (ETNB) Soars 86 Percent to Historic High on $3.5-Billion Roche Merger

#Acquired-by

Raymond James cuts 89bio to “market perform” after Roche’s $14.50 per share deal

#Acquired-by

תאגיד רוש ירכוש את חברת 89bio תמורת 2.4 מיליארד דולר מיידית, עם אופציה להכנסות נוספות עד סכום כולל לעסקה של 3.5 מיליארד דולר ● 89bio פועלת בשוק הענק של כבד שומני, אך רוש מתעניינת לא פחות במוצר של החברה לטיפול גם במחלות נוספות

#Acquired-by

Roche strikes $3.5 billion deal for U.S.-Israeli biotech 89bio | CTech

#Acquired-by

Wall Street Set to Open Higher Thursday; Jobless Claims Fall as Manufacturing Index Rebounds

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion.

#Acquired-by

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline

#Acquisition

89bio, Inc. Announces Agreement to be Acquired by Roche

#Acquired-by

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion

The company, which was founded in Israel, has a drug for treatment of fatty liver in phase III trials, which was initially an asset of Teva.

#Acquired-by

Stocks to Watch Recap: Intel, FedEx, Meta, Darden Restaurants

#Investment

Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio Buyout

#Acquisition

Sector Update: Health Care Stocks Advance Late Afternoon

Stocks Gain Pre-Bell as Fed Lowers Rates, Signals Further Policy Easing in 2025

A Closer Look at 89bio (ETNB) Valuation Following Recent Share Price Drift

H.C. Wainwright Backs 89bio (ETNB) with Buy Rating

#Product Stage #Investment

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Product Stage #Expand

89bio to Participate in Upcoming Investor Conferences

#Product Stage

89bio, Inc. (ETNB) Reports Second-Quarter Results; Leerink Partners and Citi Maintain ‘Buy’ Ratings

#Product Stage #Investment

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

#Product Stage

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Management Changes #Expand

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Product Stage #Expand

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Product Stage #Expand

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

#Product Stage

Why 89bio, Inc. (ETNB) Is Among the Best Low Priced Biotech Stocks to Buy Now

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand #Product Stage

89bio to Participate in Upcoming Investor Conferences

#Product Stage #Public Trading

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

#Product Stage #PIPE/PO

Citi says SMid biotechs alternative to large caps as it starts coverage

#Product Stage #Investment

Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now

89bio to Participate in the Leerink Partners Global Healthcare Conference

#Product Stage #Management Changes

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

#Product Stage #PIPE/PO

Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

Should You Buy 89BIO (ETNB) After Golden Cross?

Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership

89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

#PIPE/PO

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

#PIPE/PO

Why 89bio Stock Lagged the Market Today

#PIPE/PO #Product Stage

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

#PIPE/PO

Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study

89bio Provides Business Update and Outlook for 2025

#Investment #Expand #Management Changes

New Strong Sell Stocks for January 7th

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

#Layoffs

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio to Participate in the 7th Annual Evercore HealthCONx Conference

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

#Investment

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

#Investment

89bio Reports Third Quarter 2024 Financial Results and Corporate Updates

#Management Changes #Investment

89bio to Participate in the UBS Global Healthcare Conference

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH

#Customers

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings

#Investment

State Street Corp's Strategic Acquisition in 89bio Inc

#Investment #Acquisition

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

#Investment

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

#Management Changes

89bio to Participate in Upcoming Investor Conferences

#Investment

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Management Changes #Expand

89bio Appoints Francis Sarena as Chief Operating Officer

#Management Changes

89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

#Management Changes

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Management Changes #Expand

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

#Customers #Investment

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

#Investment #Expand

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials

#Investment

‘Jump on the Bandwagon,’ Says Bank of America About These 2 Stock Picks

#Acquisition #Investment

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

#Investment #Management Changes #Expand

89bio to Participate in the BofA Securities 2024 Health Care Conference

#Investment

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

#Customers

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

#Management Changes

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

#Management Changes

89bio lines up China CDMO to build API plant for commercial production of MASH candidate

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio Inc CEO Rohan Palekar Sells 52,718 Shares

#Management Changes

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

#Investment

Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That

13 Best Biotech Stocks To Buy Under $20

#Investment

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

#Investment #Expand

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio to Participate in the Leerink Partners Global Biopharma Conference

#Investment #Management Changes

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

#Investment

Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade

#Investment

89BIO (ETNB) Just Overtook the 200-Day Moving Average

Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs

#Customers

Why Akero Rocketed — And Rival 89bio Topped It — On Results In Liver Disease Treatment

89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ...

#Investment #Expand

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

#Investment #Expand

11 Best Small-Cap Growth Stocks to Invest In

#Investment

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

#Management Changes

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average

Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect?

89bio, Inc.'s (NASDAQ:ETNB) one-year returns climbed after last week's 7.0% gain, institutional investors must be happy

#Investment

89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

#Public Trading #Investment

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

#Investment #Public Trading

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

#Investment #Public Trading

89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024

#Investment #Expand

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

#Customers

89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

#Investment #Expand

89bio Inc (ETNB) Reports Increased R&D and G&A Expenses in Q3 2023

#Investment

89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

#Investment #Management Changes

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

Texas Instruments margins in for a squeeze; Silk Road walloped: 5 big analyst cuts

#Management Changes, Customers

Why Shares of 89bio Plummeted on Tuesday

#Investment

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

#Investment #Expand

89bio to Participate in the 2023 Cantor Global Healthcare Conference

#Management Changes

89bio Insider Ups Holding By 41% During Year

#Investment

89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

#Investment #Management Changes

89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

#Investment #Expand

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

#Management Changes

89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine

#Customers

Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress

#Investment #Expand

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023

#Partners

89BIO (ETNB) Just Overtook the 20-Day Moving Average

#Public Trading

89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

#Customers #Investment

Institutional investors are 89bio, Inc.'s (NASDAQ:ETNB) biggest bettors and were rewarded after last week's US$90m market cap gain

#Investment

Wall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should Know

89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

#Investment #Expand

89bio to Participate in Upcoming Investor Conferences

#Management Changes

3 Biotech Buyout Targets to Watch

Wall Street Analysts See a 79.36% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

Is 89BIO (ETNB) Outperforming Other Medical Stocks This Year?

Independent Director Michael Hayden Just Bought 41% More Shares In 89bio, Inc. (NASDAQ:ETNB)

89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock

Why Shares of 89bio Soared This Week

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

Top 1% Biotech 89bio Scores 25% Gain As Battle In Liver Disease Heats Up

#Customers #Partners

12 Best Biotech Stocks To Buy Under $20

Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Teva spin-off 89bio raises $84m in Nasdaq secondary offering

#Investment #Public Trading

89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100's Mechanism of Action Via Potent FGF Receptor Agonism BioSpace

#Customers #Management Changes

89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors

#Management Changes

Teva spin-off 89bio soars after $85m Nasdaq IPO

#Investment #Acquisition

Teva spin-off 89bio files for $70m Wall Street IPO

#Public Trading

89bio Announces Preclinical Data That Demonstrate Potential Utility of BIO89-100 for Treatment of NASH

#Customers #Investment

OrbiMed leads $60m first round in NASH treatment co 89Bio

#Investment

OrbiMed launches NASH-focused 89Bio with $60M series A, Rohan Palekar as CEO

Similar Companies

Driven by Finder AI

Primary sector

Total funding

Undisclosed

Funding stage

undefined

Number of employees

Founded

1/2018

Team Members

undefined

Contact Team

Affiliated Organizations

(undefined)

Locations

Israel

Photos & videos

(0)

No Data, yet.

Sorry, no content found under this section.

89bio Business

Business models

Product stage

Geographic markets

Products

Sector

Primary:

Target Customer

Core Technology

89bio Financials

Total funding Undisclosed

Market cap Undisclosed

Last funding Undisclosed

Funding stage undefined

Total rounds undefined

Investors undefined

Cumulative Funding Raised Over Time ($)

Public Offerings & Exits

M&A

Undisclosed

Sep 2025

Type Acquisition

Was acquired by

Roche

Undisclosed

Public Offering

$250M

Jan 2025

Stock Exchange

NASDAQ

Valuation Undisclosed

$250M

Public Offering

$125M

Nov 2024

Stock Exchange

NASDAQ

Valuation Undisclosed

$125M

Public Offering

$172.5M

Dec 2023

Stock Exchange

NASDAQ

Valuation Undisclosed

$172.5M

Public Offering

$275M

Mar 2023

Stock Exchange

NASDAQ

Valuation Undisclosed

$275M

Public Offering

$94.5M

Jun 2022

Stock Exchange

NASDAQ

Valuation Undisclosed

$94.5M

Public Offering

$84M

Jul 2020

Stock Exchange

NASDAQ

Valuation Undisclosed

$84M

Initial Public Offering EXIT

$85M

Nov 2019

Stock Exchange

NASDAQ

Valuation Undisclosed

$85M

Private Equity Funding

A Round

$60M

Oct 2018

4 Investors

$60M

89bio Lifecycle

Cumulative Funding Raised Over Time ($)

Timeline

Employees Over Time

News Over Time

Type Acquisition

Was acquired by

Roche

Undisclosed

Stock Exchange

NASDAQ

Valuation Undisclosed

$250M

Stock Exchange

NASDAQ

Valuation Undisclosed

$125M

Stock Exchange

NASDAQ

Valuation Undisclosed

$172.5M

Stock Exchange

NASDAQ

Valuation Undisclosed

$275M

Stock Exchange

NASDAQ

Valuation Undisclosed

$94.5M

Stock Exchange

NASDAQ

Valuation Undisclosed

$84M

Stock Exchange

NASDAQ

Valuation Undisclosed

$85M

A Round

$60M

Oct 2018

4 Investors

$60M

News Over Time

News Articles

Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics

#Acquisition #Partners

8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors

#Investment

Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $5.2 Billion Buyout

#Acquisition

Assessing 89bio (ETNB) Valuation Following a 60% Share Price Rally

Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash

#Acquisition

89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal

#Acquired-by

89Bio (ETNB) Soars 86 Percent to Historic High on $3.5-Billion Roche Merger

#Acquired-by

Raymond James cuts 89bio to “market perform” after Roche’s $14.50 per share deal

#Acquired-by

Roche strikes $3.5 billion deal for U.S.-Israeli biotech 89bio | CTech

#Acquired-by

Wall Street Set to Open Higher Thursday; Jobless Claims Fall as Manufacturing Index Rebounds

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion.

#Acquired-by

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline

#Acquisition

89bio, Inc. Announces Agreement to be Acquired by Roche

#Acquired-by

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion

The company, which was founded in Israel, has a drug for treatment of fatty liver in phase III trials, which was initially an asset of Teva.

#Acquired-by

Stocks to Watch Recap: Intel, FedEx, Meta, Darden Restaurants

#Investment

Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio Buyout

#Acquisition

Sector Update: Health Care Stocks Advance Late Afternoon

Stocks Gain Pre-Bell as Fed Lowers Rates, Signals Further Policy Easing in 2025

A Closer Look at 89bio (ETNB) Valuation Following Recent Share Price Drift

H.C. Wainwright Backs 89bio (ETNB) with Buy Rating

#Product Stage #Investment

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Product Stage #Expand

89bio to Participate in Upcoming Investor Conferences

#Product Stage

89bio, Inc. (ETNB) Reports Second-Quarter Results; Leerink Partners and Citi Maintain ‘Buy’ Ratings

#Product Stage #Investment

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

#Product Stage

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Management Changes #Expand

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Product Stage #Expand

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Product Stage #Expand

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

#Product Stage

Why 89bio, Inc. (ETNB) Is Among the Best Low Priced Biotech Stocks to Buy Now

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand #Product Stage

89bio to Participate in Upcoming Investor Conferences

#Product Stage #Public Trading

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

#Product Stage #PIPE/PO

Citi says SMid biotechs alternative to large caps as it starts coverage

#Product Stage #Investment

Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now

89bio to Participate in the Leerink Partners Global Healthcare Conference

#Product Stage #Management Changes

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

#Product Stage #PIPE/PO

Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

Should You Buy 89BIO (ETNB) After Golden Cross?

Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership

89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

#PIPE/PO

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

#PIPE/PO

Why 89bio Stock Lagged the Market Today

#PIPE/PO #Product Stage

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

#PIPE/PO

Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study

89bio Provides Business Update and Outlook for 2025

#Investment #Expand #Management Changes

New Strong Sell Stocks for January 7th

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

#Layoffs

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio to Participate in the 7th Annual Evercore HealthCONx Conference

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

#Investment

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

#Investment

89bio Reports Third Quarter 2024 Financial Results and Corporate Updates

#Management Changes #Investment

89bio to Participate in the UBS Global Healthcare Conference

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH

#Customers

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings

#Investment

State Street Corp's Strategic Acquisition in 89bio Inc

#Investment #Acquisition

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

#Investment

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

#Management Changes

89bio to Participate in Upcoming Investor Conferences

#Investment

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Management Changes #Expand

89bio Appoints Francis Sarena as Chief Operating Officer

#Management Changes

89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

#Management Changes

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Management Changes #Expand

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

#Customers #Investment

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

#Investment #Expand

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials

#Investment

‘Jump on the Bandwagon,’ Says Bank of America About These 2 Stock Picks

#Acquisition #Investment

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

#Investment #Management Changes #Expand

89bio to Participate in the BofA Securities 2024 Health Care Conference

#Investment

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

#Customers

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

#Management Changes

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

#Management Changes

89bio lines up China CDMO to build API plant for commercial production of MASH candidate

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio Inc CEO Rohan Palekar Sells 52,718 Shares

#Management Changes

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

#Investment

Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That

13 Best Biotech Stocks To Buy Under $20

#Investment

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

#Investment #Expand

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio to Participate in the Leerink Partners Global Biopharma Conference

#Investment #Management Changes

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

#Investment

Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade

#Investment

89BIO (ETNB) Just Overtook the 200-Day Moving Average

Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs

#Customers

Why Akero Rocketed — And Rival 89bio Topped It — On Results In Liver Disease Treatment

89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ...

#Investment #Expand

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

#Investment #Expand

11 Best Small-Cap Growth Stocks to Invest In

#Investment

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

#Management Changes

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average

Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect?

89bio, Inc.'s (NASDAQ:ETNB) one-year returns climbed after last week's 7.0% gain, institutional investors must be happy

#Investment

89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

#Public Trading #Investment

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

#Investment #Public Trading

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

#Investment #Public Trading

89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024

#Investment #Expand

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

#Customers

89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

#Investment #Expand

89bio Inc (ETNB) Reports Increased R&D and G&A Expenses in Q3 2023

#Investment

89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

#Investment #Management Changes

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

Texas Instruments margins in for a squeeze; Silk Road walloped: 5 big analyst cuts

#Management Changes, Customers

Why Shares of 89bio Plummeted on Tuesday

#Investment

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

#Investment #Expand

89bio to Participate in the 2023 Cantor Global Healthcare Conference

#Management Changes

89bio Insider Ups Holding By 41% During Year

#Investment

89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

#Investment #Management Changes

89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

#Investment #Expand

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

#Management Changes

89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine

#Customers

#Investment #Expand

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#Expand

89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023

#Partners

89BIO (ETNB) Just Overtook the 20-Day Moving Average

#Public Trading

89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

#Customers #Investment

Institutional investors are 89bio, Inc.'s (NASDAQ:ETNB) biggest bettors and were rewarded after last week's US$90m market cap gain

#Investment

Wall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should Know

89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

#Investment #Expand

89bio to Participate in Upcoming Investor Conferences

#Management Changes

3 Biotech Buyout Targets to Watch

Wall Street Analysts See a 79.36% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

Is 89BIO (ETNB) Outperforming Other Medical Stocks This Year?

Independent Director Michael Hayden Just Bought 41% More Shares In 89bio, Inc. (NASDAQ:ETNB)

89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock

Why Shares of 89bio Soared This Week

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Top 1% Biotech 89bio Scores 25% Gain As Battle In Liver Disease Heats Up

#Customers #Partners

12 Best Biotech Stocks To Buy Under $20

Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Teva spin-off 89bio raises $84m in Nasdaq secondary offering

#Investment #Public Trading

89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100's Mechanism of Action Via Potent FGF Receptor Agonism BioSpace

#Customers #Management Changes

89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors

#Management Changes

Teva spin-off 89bio soars after $85m Nasdaq IPO

#Investment #Acquisition

Teva spin-off 89bio files for $70m Wall Street IPO

#Public Trading

89bio Announces Preclinical Data That Demonstrate Potential Utility of BIO89-100 for Treatment of NASH

#Customers #Investment

OrbiMed leads $60m first round in NASH treatment co 89Bio

#Investment

OrbiMed launches NASH-focused 89Bio with $60M series A, Rohan Palekar as CEO

89bio Internal

Create note

Notes

(undefined)

Filter notes

Content Writer

undefined

BI Verification

undefined

Phone Number

undefined

Israel Register ID

undefined

Confidence Score

undefined

Missing Fields

undefined

Profile Creator

undefined

Profile Update

undefined

Recent Updates

undefined

Create a free account to:

Startup Nation Finder

Your CSV is on the way

Upgrade your Finder plan

Provide your business email

Verify your business email

Create Watchlist

Add to List

Notifications settings

Email Alerts

No Notifications are selected

Suggest Edits

Thank You

Claim Profile

Password must contain:

Verify your email

Reset password

Check your mailbox

Password recovery

Tell us more about you

Save Search

Rename Search

Share saved search with others

Add to list

89bio Overview

Cumulative Funding Raised Over Time ($)

Employees Over Time

89bio Climate Tech relevance

Latest News

No Data, yet.

Similar Companies

Primary sector

Total funding

Funding stage

Number of employees

Founded

Team Members

Affiliated Organizations

Web & social links

Locations

Israel

Offices Abroad

Photos & videos

No Data, yet.

89bio Business

Business models

Product stage

Geographic markets

Products

Sector

Target Customer

Core Technology

Use Cases

Tech Community Involvement

Tags

89bio Financials

Cumulative Funding Raised Over Time ($)

No Data, yet.

Public Offerings & Exits

Private Equity Funding

Non-Equity Funding

Mergers and Acquisitions

89bio Lifecycle

Cumulative Funding Raised Over Time ($)

Timeline

Employees Over Time

News Over Time

No Data, yet.

89bio News

News Over Time

No Data, yet.

News Articles

Related Content

89bio Team

No Data, yet.

Employees Over Time

Similar Companies

89bio Internal

Create note

Notes

Add Article